Rotenone affects p53 transcriptional activity and apoptosis via targeting SIRT1 and H3K9 acetylation in SH-SY5Y cells

Journal of Neurochemistry

Volumn 134, Issue 4, 2015, Pages 668-676

  Feng, Ya ^a   Liu, Te ^b   Dong, Su Yan ^a   Guo, Yan Jie ^a   Jankovic, Joseph ^c   Xu, Huaxi ^d,e   Wu, Yun Cheng ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d XIAMEN UNIVERSITY   (China)

^e BURNHAM INSTITUTE   (United States)

Author keywords

H3K9 ac; H3K9 me3; p53; resveratrol; SIRT1

Indexed keywords

HISTONE H3; LYSINE; PROTEIN P53; RESVERATROL; ROTENONE; SIRTUIN 1; HISTONE; SIRT1 PROTEIN, MOUSE;

APOPTOSIS; ARTICLE; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; NEUROPROTECTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; ACETYLATION; CELL SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ACETYLATION; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; GENES, P53; HISTONES; HUMANS; ROTENONE; SIRTUIN 1; TRANSCRIPTION, GENETIC;

EID: 84937816175     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13172     Document Type: Article

References (36)

1. Agarwal R., Liebe S., Turski M. L., et al,. (2014) Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discov. Med. 18, 331-339.
2. Bernhaus A., Ozsvar-Kozma M., Saiko P., et al,. (2009) Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. Invest. New Drugs 27, 393-401.
3. Checler F., (2014) Alves da Costa C. p53 in neurodegenerative diseases and brain cancers. Pharmacol Ther. 142, 99-113.
4. Clasen B. F., Poulsen M. M., Escande C., Pedersen S. B., Moller N., Chini E. N., Jessen N., and, Jorgensen J. O., (2014) Growth hormone signaling in muscle and adipose tissue of obese human subjects: associations with measures of body composition and interaction with resveratrol treatment. J. Clin. Endocrinol. Metab. 99, E2565-E2573.
5. Dragicevic E., Poetschke C., Duda J., et al,. (2014) Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons. Brain 137, 2287-2302.
6. Feng Y., Jankovic J., and, Wu Y. C., (2015) Epigenetic mechanisms in Parkinson's disease. J. Neurol. Sci. 349, 3-9.
7. Ferretta A., Gaballo A., Tanzarella P., et al,. (2014) Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson's disease. Biochim. Biophys. Acta 1842, 902-915.
8. Ghavami S., Shojaei S., Yeganeh B., et al,. (2014) Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog. Neurobiol. 112, 24-49.
9. Hao Q., and, Cho W. C., (2014) Battle against cancer: an everlasting saga of p53. Int. J. Mol. Sci. 15, 22109-22127.
10. Hernandez-Jimenez M., Hurtado O., Cuartero M. I., Ballesteros I., Moraga A., Pradillo J. M., McBurney M. W., Lizasoain I., and, Moro M. A., (2013) Silent information regulator 1 protects the brain against cerebral ischemic damage. Stroke 44, 2333-2337.
11. Kulkarni S. S., and, Canto C., (2015) The molecular targets of resveratrol. Biochimica et biophysica acta. 1852, 1114-1123.
12. Langley E., Pearson M., Faretta M., Bauer U. M., Frye R. A., Minucci S., Pelicci P. G., and, Kouzarides T., (2002) Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21, 2383-2396.
13. de la Lastra C. A., and, Villegas I., (2005) Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res. 49, 405-430.
14. Lim L. S., Hong F. H., Kunarso G., and, Stanton L. W., (2010) The pluripotency regulator Zic3 is a direct activator of the Nanog promoter in ESCs. Stem cells 28, 1961-1969.
15. Lin J. N., Lin V. C., Rau K. M., Shieh P. C., Kuo D. H., Shieh J. C., Chen W. J., Tsai S. C., and, Way T. D., (2010) Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J. Agric. Food Chem. 58, 1584-1592.
16. Lin T. K., Chen S. D., Chuang Y. C., et al,. (2014) Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through induction of heme oxygenase-1 dependent autophagy. Int. J. Mol. Sci. 15, 1625-1646.
17. Lu X., Kim-Han J. S., Harmon S., Sakiyama-Elbert S. E., and, O'Malley K. L., (2014) The Parkinsonian mimetic, 6-OHDA, impairs axonal transport in dopaminergic axons. Mol. Neurodegener. 9, 17.
18. Luo J., Nikolaev A. Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., and, Gu W., (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107, 137-148.
19. Mao Y. R., Jiang L., Duan Y. L., An L. J., and, Jiang B., (2007) Efficacy of catalpol as protectant against oxidative stress and mitochondrial dysfunction on rotenone-induced toxicity in mice brain. Environ. Toxicol. Pharmacol. 23, 314-318.
20. Marouco D., Garabadgiu A. V., Melino G., and, Barlev N. A., (2013) Lysine-specific modifications of p53: a matter of life and death? Oncotarget 4, 1556-1571.
21. Mudo G., Makela J., Di Liberto V., et al,. (2012) Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell. Mol. Life Sci. 69, 1153-1165.
22. Neuhaus J. F., Baris O. R., Hess S., Moser N., Schroder H., Chinta S. J., Andersen J. K., Kloppenburg P., and, Wiesner R. J., (2014) Catecholamine metabolism drives generation of mitochondrial DNA deletions in dopaminergic neurons. Brain 137, 354-365.
23. Okawara M., Katsuki H., Kurimoto E., Shibata H., Kume T., and, Akaike A., (2007) Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem. Pharmacol. 73, 550-560.
24. Pal R., Monroe T. O., Palmieri M., Sardiello M., and, Rodney G. G., (2014) Rotenone induces neurotoxicity through Rac1-dependent activation of NADPH oxidase in SHSY-5Y cells. FEBS Lett. 588, 472-481.
25. Pan T., Kondo S., Le W., and, Jankovic J., (2008) The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 131, 1969-1978.
26. Petegnief V., and, Planas A. M., (2013) SIRT1 regulation modulates stroke outcome. Transl. Stroke Res. 4, 663-671.
27. Saunders L. R., and, Verdin E., (2007) Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26, 5489-5504.
28. Schapira A. H., Olanow C. W., Greenamyre J. T., and, Bezard E., (2014) Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 384, 545-555.
29. Shinozaki S., Chang K., Sakai M., et al,. (2014) Inflammatory stimuli induce inhibitory S-nitrosylation of the deacetylase SIRT1 to increase acetylation and activation of p53 and p65. Sci. Signal. 7, ra106.
30. Soleas G. J., Diamandis E. P., and, Goldberg D. M., (2001) The world of resveratrol. Adv. Exp. Med. Biol. 492, 159-182.
31. Sunico C. R., Nakamura T., Rockenstein E., et al,. (2013) S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson's disease. Mol. Neurodegener. 8, 29.
32. Tamaki N., Cristina Orihuela-Campos R., Inagaki Y., Fukui M., Nagata T., and, Ito H. O., (2014) Resveratrol improves oxidative stress and prevents the progression of periodontitis via the activation of the Sirt1/AMPK and the Nrf2/antioxidant defense pathways in a rat periodontitis model. Free Radic. Biol. Med. 75, 222-229.
33. Vaziri H., Dessain S. K., Ng Eaton E., Imai S. I., Frye R. A., Pandita T. K., Guarente L., and, Weinberg R. A., (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107, 149-159.
34. Vousden K. H., (2000) p53: death star. Cell 103, 691-694.
35. Wang L. M., Wang Y. J., Cui M., Luo W. J., Wang X. J., Barber P. A., and, Chen Z. Y., (2013) A dietary polyphenol resveratrol acts to provide neuroprotection in recurrent stroke models by regulating AMPK and SIRT1 signaling, thereby reducing energy requirements during ischemia. Eur. J. Neuorsci. 37, 1669-1681.
36. Wu Y., Li X., Zhu J. X., Xie W., Le W., Fan Z., Jankovic J., and, Pan T., (2011) Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals 19, 163-174.